Proxy Votes Now

Home › Activist investors › Caligan Partners

Caligan Partners

Campaign activist. Positions and campaigns from Caligan Partners’s SEC filings. Updated November 20, 2026.

Filer entities
Caligan Partners LP
SEC CIK
1727492 (Caligan Partners LP)
SEC filings
Schedule 13D filings · 13F reports · soliciting material
Latest 13F
Quarter ended Sep 30, 2026, filed Nov 16, 2026: 26 US-listed positions reported; 16 of 1% or more of a company without a 13D are listed below.
20current positions
10new or changed in 90 days
0active campaigns
3campaigns on record

Active campaigns

No active campaign by this definition (see How to read this).

Current positions (20)

CompanyStakeSourceFirst disclosedLast changeSince previous filingFlagsStated intent
SAB Biotherapeutics, Inc. 9.70%8,736,898 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 2, 2026 May 15, 2026 Increased Nov 16, 2026 ▲ 0.94 pts Increased 13F: none stated
Sagimet Biosciences Inc. 8.58%2,794,484 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Mar 31, 2026 Aug 14, 2026 Increased Nov 16, 2026 ▲ 0.90 pts Increased 13F: none stated
Avalo Therapeutics, Inc. 5.65%3,268,303 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 2, 2026 Nov 14, 2025 Increased Nov 16, 2026 ▼ 0.25 pts Increased 13F: none stated
LB Pharmaceuticals Inc 4.66%1,509,621 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 3, 2026 May 15, 2026 Increased Nov 16, 2026 ▲ 0.21 pts Increased 13F: none stated
Aura Biosciences, Inc. 4.43%4,590,253 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 6, 2026 Aug 14, 2025 Increased Nov 16, 2026 ▲ 0.28 pts Increased 13F: none stated
Sensei Biotherapeutics, Inc. 3.44%890,210 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 30, 2026 May 15, 2026 Increased Nov 16, 2026 ▲ 1.01 pts Increased 13F: none stated
Immunocore Holdings Plc 3.24%1,672,141 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 31, 2026 Aug 14, 2026 Increased Nov 16, 2026 ▲ 0.55 pts Increased 13F: none stated
Artiva Biotherapeutics, Inc. 3.03%1,481,043 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Jul 31, 2026 Aug 14, 2026 Decreased Nov 16, 2026 ▼ 0.52 pts Decreased 13F: none stated
ADMA Biologics, Inc. 2.65%5,875,007 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 30, 2026 May 15, 2023 Increased Nov 16, 2026 ▲ 0.09 pts Increased 13F: none stated
Tyra Biosciences, Inc. 1.53%910,749 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Jul 31, 2026 May 15, 2025 Increased Nov 16, 2026 ▲ 0.17 pts Increased 13F: none stated
Verrica Pharmaceuticals Inc. 10.0%6,503,054 shares Schedule 13D/A, filed Dec 30, 2025 Nov 24, 2025 — 0.00 pts — Standard Item 4 language
Anika Therapeutics, Inc. 9.9%1,435,130 shares Schedule 13D/A, filed Jan 27, 2026 Aug 17, 2023 — 0.00 pts — Seeks changes or engagement
Opus Genetics, Inc. 7.16%5,960,972 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 3, 2026 May 15, 2026 — ▼ 0.14 pts — 13F: none stated
Cellectar Biosciences Inc. 4.97%469,998 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 11, 2026 Aug 14, 2026 — 0.00 pts — 13F: none stated
Vor Biopharma Inc. 3.13%1,925,066 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 26, 2026 Feb 17, 2026 — ▼ 0.12 pts — 13F: none stated
Viridian Therapeutics, Inc. 1.93%2,193,981 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 2, 2026 Aug 14, 2026 — 0.00 pts — 13F: none stated
Tango Therapeutics, Inc. 1.48%2,501,246 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 4, 2026 Feb 17, 2026 — 0.00 pts — 13F: none stated
Vaxcyte, Inc. 1.38%2,188,636 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 2, 2026 Feb 17, 2026 — ▼ 0.09 pts — 13F: none stated
Exelixis, Inc. — Schedule 13D/A, filed Jun 2, 2023stake not read from this filing’s format: see the filing Jun 2, 2023 — — — Standard Item 4 language
Liquidia Corp — Schedule 13D/A, filed Sep 12, 2024stake not read from this filing’s format: see the filing Dec 14, 2023 — — — Standard Item 4 language

Stake: the latest 13D’s percent of the class (the largest single reporting person’s, as filed), or for a 13F the reported shares as a percent of the company’s shares outstanding on the date shown. Since previous filing: the change in percentage points against the investor’s previous 13D on the company, or its previous 13F.

Stated intent (13D Item 4)

Item 4 of a Schedule 13D (“Purpose of Transaction”) is where the investor states its plans. The label is a plain reading of that text; the excerpt is quoted from the filing.

Verrica Pharmaceuticals Inc. · Standard Item 4 language

“On December 26, 2025, pursuant to the Purchase Agreement, the Issuer appointed Dr. Charles Frantzreb, a designee selected by Caligan, as a Class I member of the Board, effective immediately.”

Item 4 in the Schedule 13D/A filed Dec 30, 2025.

Anika Therapeutics, Inc. · Seeks changes or engagement

“Item 4 of the Schedule 13D is hereby amended and supplemented by the addition of the following: On May 28, 2024, the Reporting Persons and certain of their affiliates entered into a Cooperation Agreement with the Issuer (the “ Cooperation Agreement ”). Pursuant to the Cooperation Agreement, Caligan withdrew its prior nomination of individuals to the Board of Directors (the “ Board ”) of the Issuer and the Issuer appointed William Jellison (one of the individuals Caligan nominated…”

Item 4 in the Schedule 13D/A filed Jan 27, 2026; this amendment did not restate Item 4, so the text is from the filing of May 30, 2024.

Exelixis, Inc. · Standard Item 4 language

“Item 4 of the Schedule 13D is hereby amended and supplemented by the addition of the following: On May 31, 2023, Mr. Johnson was elected to the board of directors of the Issuer at the 2023 Annual Meeting. As a result, the Nomination Agreement terminated in accordance with its terms.”

Item 4 in the Schedule 13D/A filed Jun 2, 2023.

Liquidia Corp · Standard Item 4 language

“Item 4 of the Schedule 13D is hereby amended and supplemented by the addition of the following: On September 10, 2024, certain Caligan Funds entered into a Common Stock Purchase Agreement (the “ 2024 Purchase Agreement ”) with the Issuer for the purchase from the Issuer in a private placement (the “ 2024 Private Placement” ) of an aggregate of 1,123,595 shares (the “ 2024 Private Placement Shares”

Item 4 in the Schedule 13D/A filed Sep 12, 2024.

Campaigns are compiled from SEC filings (13D, proxy contest filings and settlement 8-Ks); campaigns run without SEC filings, e.g. by public letter below the 5% threshold, may not appear.

Past campaigns (3)
CompanyOutcome or last statusDateFirst filingHighest stageFilingsMeeting / votes
Anika Therapeutics, Inc.Board seats Settled (agreement with the company) May 28, 2024 Feb 21, 2023 Proxy contest filed (preliminary proxy) latest (9) —
Amag Pharmaceuticals, Inc.Board seats No campaign filings in the last 12 months Sep 26, 2019 Sep 4, 2019 Proxy contest filed latest (6) —
Knowles CorpBoard seats No campaign filings in the last 12 months Apr 18, 2019 Mar 29, 2019 Proxy contest filed latest (6) —
Past positions (2)
CompanyLast stakeSourceOutcomeDate
Alimera Sciences Inc — Schedule 13D/A, filed Sep 18, 2024stake not read from this filing’s format: see the filing Reported below 5% in a 13D/A Sep 18, 2024
Standard Biotools Inc. — Schedule 13D/A, filed Jan 8, 2024stake not read from this filing’s format: see the filing Not in the 13F for the quarter ended Mar 31, 2024 May 13, 2024

How large managers voted in Caligan Partners’s proxy contests (meetings since July 2023)

Fund votes come from Form N-PX filings, which this site holds from July 1, 2023 (meetings through June 30, 2026; later meetings appear when the managers file their next N-PX); earlier contests and campaigns that settled before a vote are listed under the activist’s campaigns.

No proxy contest has gone to a vote since July 1, 2023.

Track record

How each campaign on record ended, as read from the filings: settlements disclosed in the company’s 8-K or the investor’s 13D, contested votes (8-K Item 5.07), withdrawals and 13D amendments below 5%.

1Settlement
2No outcome in the filings read
Outcome of each campaign (3)
CompanyOutcomeDetailDateFirst filing
Anika Therapeutics, Inc. Settlement agreement with the company May 30, 2024 Feb 21, 2023
Amag Pharmaceuticals, Inc. No outcome in the filings read — Sep 26, 2019 Sep 4, 2019
Knowles Corp No outcome in the filings read — Apr 18, 2019 Mar 29, 2019

Share price after the first 13D

The change in the company’s closing share price from the first trading day on or before the investor’s first Schedule 13D to the latest close, and to 6 and 12 months after it, beside the S&P 500 (SPY) over the same dates. This is a price change after a filing date: it is not attributed to the investor, and it is not the investor’s return. Coverage: 1 of 6 13D positions have prices (the site’s daily price history starts November 10, 2025, and covers only listed tickers it tracks).

CompanyFirst 13DTo latest closeSPY same dates6 months after12 months after
Verrica Pharmaceuticals Inc. VRCA Nov 24, 2025 -39.5%Nov 24, 2025 – Nov 18, 2026 +9.2% +27.5%SPY +12.2% not yet / no price

Prices: daily closes (Nasdaq), as stored by the site.

Settlement terms

Terms of the cooperation agreements, read by rules from the company’s Form 8-K (or the investor’s 13D where it describes the agreement). Each term is quoted from the filing; terms a rule did not find are not listed, so a missing term is not evidence that the agreement lacks it.

Anika Therapeutics, Inc. · May 30, 2024 · Directors named, Ownership cap, Committee role, Board seats, Standstill, Voting commitment

Other disclosed holders around the same time

Filings by other activists on this list (their first 13D or 13F on the company) and by other holders of 5% or more (Schedule 13D or 13G) dated within 180 days of Caligan Partners’s first disclosure in the same company. They are listed together by date only; nothing here says the holders act together.

Viridian Therapeutics, Inc. · Caligan Partners first disclosed Aug 14, 2026 · 7 other filings
HolderFormDateStake
Kynam Capital Management, LP Schedule 13G Feb 17, 2026 1.5%
Deep Track Capital, LP Schedule 13G May 8, 2026 5.3%
Bellevue Group AG Schedule 13G May 15, 2026 6.6%
Paradigm BioCapital Advisors LP Schedule 13G Jun 26, 2026 5.1%
State Street Corporation Schedule 13G Aug 7, 2026 5.5%
T. Rowe Price Associates, Inc. Schedule 13G Aug 14, 2026 5.2%
Point72 Asset Management, L.P. Schedule 13G Aug 20, 2026 5.0%
Immunocore Holdings Plc · Caligan Partners first disclosed Aug 14, 2026 · 4 other filings
HolderFormDateStake
T. Rowe Price Investment Management, Inc. Schedule 13G Feb 17, 2026 11.8%
Vestal Point Capital, LP Schedule 13G May 15, 2026 5.5%
FMR LLC Schedule 13G Aug 6, 2026 8.8%
Wellington Management Group LLP Schedule 13G Aug 13, 2026 11.6%
Sagimet Biosciences Inc. · Caligan Partners first disclosed Aug 14, 2026 · 2 other filings
HolderFormDateStake
Nantahala Capital 13F Nov 13, 2026 1.4%
Ra Capital Management, L.P. 13F Nov 16, 2026 5.5%
Vaxcyte, Inc. · Caligan Partners first disclosed Feb 17, 2026 · 6 other filings
HolderFormDateStake
FMR LLC Schedule 13G Sep 8, 2025 10.1%
T. Rowe Price Investment Management, Inc. Schedule 13G Nov 14, 2025 6.4%
Janus Henderson Group PLC Schedule 13G Nov 14, 2025 10.1%
Vanguard Capital Management Schedule 13G Apr 30, 2026 5.0%
RA Capital Management, L.P. Schedule 13G May 15, 2026 8.9%
JANUS HENDERSON GROUP Ltd. Schedule 13G Aug 7, 2026 0.1%
Tango Therapeutics, Inc. · Caligan Partners first disclosed Feb 17, 2026 · 13 other filings
HolderFormDateStake
Raymond Debbane Schedule 13G Sep 22, 2025 5.3%
Farallon Partners, L.L.C. Schedule 13G Nov 12, 2025 9.3%
Adage Capital Management, L.P. Schedule 13G Nov 13, 2025 2.3%
TCG Crossover GP II, LLC Schedule 13G Nov 14, 2025 6.3%
BlackRock, Inc. Schedule 13G Jan 21, 2026 6.3%
The Vanguard Group Schedule 13G Jan 30, 2026 5.0%
Woodline Partners LP Schedule 13G Feb 17, 2026 7.5%
TCG Crossover GP II, L.P. Schedule 13G Feb 17, 2026 10.0%
FMR LLC Schedule 13G May 6, 2026 6.9%
RTW Investments, LP Schedule 13G May 15, 2026 9.3%
Nextech Crossover I GP S.a. r.l. Schedule 13G May 15, 2026 5.1%
The Goldman Sachs Group, Inc. Schedule 13G Aug 14, 2026 6.0%
Farallon Capital Management, L.L.C. Schedule 13G Aug 14, 2026 9.8%
Vor Biopharma Inc. · Caligan Partners first disclosed Feb 17, 2026 · 2 other filings
HolderFormDateStake
ForGrowth III PA B.V. Schedule 13D Dec 23, 2025 10.0%
Nantahala Capital 13F Aug 14, 2026 1.5%
Verrica Pharmaceuticals Inc. · Caligan Partners first disclosed Nov 24, 2025 · 1 other filing
HolderFormDateStake
Cannell Capital 13F May 15, 2026 4.0%
Standard Biotools Inc. · Caligan Partners first disclosed Jul 3, 2023 · 1 other filing
HolderFormDateStake
Viking Global Investors LP Schedule 13D Oct 16, 2023 9.5%

How to read this

Flags (last 90 days)
New first disclosed in the last 90 days. Increased / Decreased shares up or down in a 13D/A or 13F filed in that time. Below 5% a 13D/A reported less than 5%, the reporting threshold. Exited a 13D/A reported no shares, or the investor’s 13F no longer lists a company it listed before.
Active campaign
A contested meeting at which the investor is soliciting proxies is still to be held; or in the last 12 months it filed a proxy-contest document (PREC14A, DEFC14A or DFAN14A soliciting material), stated in a 13D that it nominated directors, filed a letter or presentation to the board or shareholders, or stated public demands in a 13D — and no settlement, withdrawal, contested vote or 13D below 5% is dated on or after the latest such filing. Status is the furthest step since then: Public demands in a 13D < Public letter or soliciting material < Nominations made < Proxy contest filed.
Sources and limits
SEC EDGAR only. 13D data covers filings since June 2023; 13F reports are quarterly and filed up to 45 days after the quarter, and do not show swaps, most options or non-US holdings. Settlements are cooperation agreements disclosed in the company’s 8-K or stated in the investor’s 13D; board seats are read from the 8-K. Text marked Summary of the filing is checked against the filing, whose words are quoted beside it. Nothing on this page predicts what the investor will do.